PubMed Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight Supports head-to-head context when pages compare older and newer GLP-1 options
Cell 124 , 783801 (2006)
What Happens When You Stop GLP-1s And How to Prevent Weight Regain GLP-1 medications like Wegovy, and Mounjaro have helped millions of people lose weight by reducing appetite and improving metabolic health
But this does not substitute for controlled trials, and patients should understand they are, in effect, early adopters of an approach that is not yet evidence-based in the traditional sense
Disclaimer: This article is educational and is not medical, tax, or benefits advice
Several factors explain the lack of approval: insufficient clinical trials (no completed Phase 3 trials for most indications), safety concerns (FDA has identified specific adverse events), commercial considerations (patent status affects development investment), regulatory pathway (approval requires specific, rigorous documentation), and competition (Tesamorelin already approved for related indication)
